Status:
COMPLETED
Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC
Lead Sponsor:
Institut Claudius Regaud
Conditions:
Triple Negative Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The prescription of neoadjuvant chemotherapy becomes a standard in women with HER2-positive or triple-negative breast cancer and allows a complete histological response (pCR) which represents a progno...
Detailed Description
Retrospective and monocentric translational study carried out on patients treated at the IUCT-Oncopole by neoadjuvant chemotherapy (sequential treatment FEC100 or EC100 then taxane, paclitaxel weekly ...
Eligibility Criteria
Inclusion
- Samples from triple negative BC patients, patients treated by neoadjuvant chemotherapy ( FEC or EC than taxanes) Patients consent to use their samples.
Exclusion
- Samples not available before or after neoadjuvant chemotherapy
Key Trial Info
Start Date :
June 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04368468
Start Date
June 15 2020
End Date
January 31 2021
Last Update
December 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut claudius regaud
Toulouse, France, 31059